Singapore scientists discover novel therapeutic target to advance treatment of diabetic eye diseases
December 27th 2022According to investigators, the study demonstrated that by restoring the function of ADAM10, a major shedding protein, it was possible in preclinical models to control the abnormal formation of blood vessels, offering an attractive therapeutic target to treat DR.
Read More
Pixium Vision finishes implantations in its European PRIMAvera pivotal trial in atrophic dry AMD
December 20th 2022The company confirms target read-out around the end of 2023 and regulatory submission in Europe in H1 2024. The data will also play an important supporting role in U.S. regulatory submission.
Read More
EyeCon 2022: Ophthalmology Times co-chairs discuss highlights of Day 1
December 17th 2022Ophthalmology Times®' EyeCon co-chairs Peter J. McDonnell, MD, director of the Wilmer Eye Institute, and glaucoma specialist Oluwatosin U. Smith MD, from Glaucoma Associates of Texas, discuss some of the highlights of EyeCon 2022.
Read More
Ocuphire Pharma submits New Drug Application to FDA for Nyxol eye drops for reversal of mydriasis
December 6th 2022According to the company, the NDA is supported by positive phase data demonstrating the rapid reversal of dilated eyes and favorable safety profile in pediatric and adult subjects.
Read More